SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sensus Healthcare Inc (SRTS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators are mildly positive, the company's recent financial performance is significantly weak, and there are no strong positive catalysts or recent news to support a bullish outlook. Analysts maintain a Buy rating, but the lowered price targets and lack of significant trading trends suggest caution. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this investment is recommended.
The MACD is positive and contracting (0.0345), indicating mild bullish momentum. The RSI is neutral at 46.632, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 4.28, with resistance at 4.719 and support at 3.841.
Potential revenue growth expected in 2026 due to new reimbursement codes.
Lack of recent news or significant trading trends. Stock trend analysis predicts a slight decline over the next day, week, and month.
In Q4 2025, revenue dropped to $4.939M (-62.20% YoY), net income fell to -$3.167M (-304.85% YoY), EPS declined to -$0.19 (-311.11% YoY), and gross margin decreased to 38.43% (-29.34% YoY).
Alliance Global initiated coverage with a Buy rating and a $7.50 price target, citing potential revenue growth in 2026. Maxim lowered the price target from $8 to $6 due to weak Q4 results but maintained a Buy rating.
